Drug Cut Genetic Cholesterol 78%, But Heart Risks Didn't Fall | EURweb | Black News, Culture, Entertainment & More
Novartis' experimental drug pelacarsen reduced lipoprotein(a) by 78% in a Phase 3 trial but failed to lower heart attack or stroke risk. The study involved 8,322 patients with elevated Lp(a) and prior cardiovascular events. Despite the significant reduction, the drug did not outperform a placebo. Novartis is halting development of the drug, while other companies continue testing Lp(a) treatments.
How this was made
The 30-second read
Why it matters
The result challenges the commercial viability of pelacarsen and may prompt Novartis to re‑evaluate its cardiovascular pipeline.
Market read
First‑report of a major Phase 3 failure for a high‑profile cholesterol drug; likely to affect Novartis stock and broader biotech sentiment.
What to watch
Potential for alternative indications, future formulation improvements, or partnership opportunities that could revive the program.
Background
The Horizon Phase 3 trial enrolled 8,322 patients with elevated Lp(a) and prior cardiovascular events. Despite a 78% biomarker reduction, the primary endpoint of major cardiovascular events was not met.
Ticker impact
Novartis announced its Phase 3 Horizon trial of pelacarsen reduced Lp(a) by 78% but did not lower major cardiovascular events versus placebo.
likely downward pressure as the market prices in the failed trial result
Phase‑3 data is a primary disclosure; a large‑cap pharma with a high‑profile program failing to meet its endpoint typically triggers a sell‑off.
Market effects
May dampen enthusiasm for Lp(a)‑lowering therapies across the biotech sector.
US biotech equities could see modest pullback on the news.
Could influence global cholesterol‑lowering drug pipelines and related R&D investments.
Counterpoint
Some investors may view the trial as a step toward eventual approval, betting on later data or combination strategies.
Key entities
- CompanyNovartis
Swiss‑based pharmaceutical giant developing pelacarsen.
- DrugPelacarsen
Experimental Lp(a)‑lowering therapy.
